Granted Patent B2

US 12,553,084 · App. 17/554,195 · Granted Feb 17, 2026

Inventors: Richard P. Rava (Redwood City, CA); Brian Kent Rhees (Chandler, AZ)

Assignee: VERINATA HEALTH, INC.

C12Q1/6869C12Q1/6806C12Q1/6809G16B20/10G16B30/10G16H10/40C12Q1/6883C12Q2600/106C12Q2600/112

Abstract

Claims (59)

1 . A method for identifying fetal trisomy 21, said method comprising the steps:

(a) sequencing at least a portion of fetal and maternal nucleic acids of a maternal blood sample to obtain sequence information;

(b) identifying and counting within said sequence information the number of mapped sequence tag that map to chromosome 21;

(c) identifying and counting within said sequence information the number of mapped sequence tags that map to at least one normalizing chromosome;

(d) using said number of mapped sequence tags identified for chromosome 21 in step (b) and said number of mapped sequence tags identified for said at least one normalizing chromosome in step (c) to calculate a chromosome dose for chromosome 21;

wherein step (d) comprises:

(i) calculating a sequence tag density ratio for chromosome 21, by relating said number of mapped sequence tags identified for chromosome 21 in step (b) to the length of chromosome 21;

(ii) calculating a sequence tag density ratio for said at least one normalizing chromosome, by relating said number of mapped sequence tags identified for said at least one normalizing chromosome in step (c) to the length of said at least one normalizing chromosome; and

(iii) using the sequence tag density ratios calculated in steps (i) and (ii) to calculate the chromosome dose for chromosome 21, wherein said chromosome dose is calculated as a ratio of said sequence tag density ratio for chromosome 21 and said sequence tag density ratio for said at least one normalizing chromosome; and

(e) comparing said chromosome dose to at least one threshold value, and thereby identifying the presence or absence of fetal trisomy 21,

wherein said normalizing chromosome is a chromosome or group of chromosomes selected from chromosome 9, chromosome 1, chromosome 2, chromosome 3, chromosome 4, chromosome 5, chromosome 6, chromosome 7, chromosome 8, chromosome 10, chromosome 11, chromosome 12, chromosome 13, chromosome 14, chromosome 15, chromosome 16, and chromosome 17;

wherein at least 3×10 6 mapped sequence tags are identified for chromosome 21 in step (b); and

wherein each mapped sequence tag maps uniquely to the human genome.

2 . The method of claim 1 , wherein said fetal and maternal nucleic acid molecules are cell-free DNA molecules.

3 . The method of claim 1 , wherein said sequencing is performed on an amplified library preparation.

4 . The method of claim 1 , wherein said sequencing is next generation sequencing (NGS).

5 . The method of claim 1 , wherein said sequencing is massively parallel sequencing-by-synthesis with reversible dye terminators.

6 . The method of claim 1 , wherein said sequencing is sequencing-by-ligation.

7 . The method of claim 1 , wherein said sequencing is single molecule sequencing.

8 . A method for identifying fetal trisomy 18, said method comprising the steps:

(a) sequencing at least a portion of fetal and maternal nucleic acids of a maternal blood sample to obtain sequence information;

(b) identifying and counting within said sequence information the number of mapped sequence tags that map to chromosome 18;

(c) identifying and counting within said sequence information the number of mapped sequence tags for at least one normalizing chromosome;

(d) using said number of mapped sequence tags identified for chromosome 18 in step (b) and said number of mapped sequence tags identified for the at least one normalizing chromosome in step (c) to calculate a chromosome dose for chromosome 18;

wherein step (d) comprises:

(i) calculating a sequence tag density ratio for chromosome 18, by relating said number of mapped sequence tags identified for chromosome 18 in step (b) to the length of chromosome 18;

(ii) calculating a sequence tag density ratio for said at least one normalizing chromosome, by relating said number of mapped sequence tags identified for said at least one normalizing chromosome in step (c) to the length of said at least one normalizing chromosome; and

(iii) using the sequence tag density ratios calculated in steps (i) and (ii) to calculate the chromosome dose for chromosome 18, wherein said chromosome dose is calculated as a ratio of said sequence tag density ratio for chromosome 18 and said sequence tag density ratio for said at least one normalizing chromosome; and

(e) comparing said chromosome dose to at least one threshold value, and thereby identifying the presence or absence of fetal trisomy 18,

wherein said normalizing chromosome is a chromosome or group of chromosomes selected from chromosome 8, chromosome 2, chromosome 3, chromosome 4, chromosome 5, chromosome 6, chromosome 7, chromosome 9, chromosome 10, chromosome 11, chromosome 12, chromosome 13, and chromosome 14;

wherein at least 3×10 6 mapped sequence tags are identified for chromosome 18 in step (b); and

wherein each mapped sequence tag maps uniquely to the human genome.

9 . The method of claim 8 , wherein said sequencing comprises:

massively parallel sequencing-by-synthesis with reversible dye terminators;

sequencing-by-ligation; or

single molecule sequencing.

10 . The method of claim 8 , wherein said sequencing is performed on an amplified library preparation.

11 . The method of claim 8 , wherein said sequencing is next generation sequencing (NGS).

12 . The method of claim 8 , wherein said fetal and maternal nucleic acid molecules are cell-free DNA molecules.

13 . A method for identifying fetal trisomy 13, said method comprising the steps:

(a) sequencing at least a portion of fetal and maternal nucleic acids of a maternal blood sample to obtain sequence information;

(b) identifying and counting within the sequence information the number of mapped sequence tags that map to chromosome 13;

(c) identifying and counting within the sequence information the number of mapped sequence tags that map to at least one normalizing chromosome;

(d) using said number of mapped sequence tags identified for chromosome 13 in step (b) and said number of mapped sequence tags identified for the at least one normalizing chromosome in step (c) to calculate a chromosome dose for chromosome 13;

wherein step (d) comprises:

(i) calculating a sequence tag density ratio for chromosome 13, by relating said number of mapped sequence tags identified for chromosome 13 in step (b) to the length of chromosome 13;

(ii) calculating a sequence tag density ratio for said at least one normalizing chromosome, by relating said number of mapped sequence tags identified for said at least one normalizing chromosome in step (c) to the length of said at least one normalizing chromosome; and

(iii) using the sequence tag density ratios calculated in steps (i) and (ii) to calculate the chromosome dose for chromosome 13, wherein said chromosome dose is calculated as a ratio of said sequence tag density ratio for chromosome 13 and said sequence tag density ratio for said at least one normalizing chromosome; and

(e) comparing said chromosome dose to at least one threshold value, and thereby identifying the presence or absence of fetal trisomy 13,

wherein said normalizing chromosome is a chromosome or group of chromosomes selected from chromosome 2, chromosome 3, chromosome 4, chromosome 5, chromosome 6, chromosome 7, chromosome 8, chromosome 9, chromosome 10, chromosome 11, chromosome 12, chromosome 14, chromosome 18, and chromosome 21;

wherein at least 3×10 6 mapped sequence tags are identified for chromosome 13 in step (b); and

wherein each mapped sequence tag maps uniquely to the human genome.

14 . The method of claim 13 , wherein said fetal and maternal nucleic acid molecules are cell-free DNA molecules.

15 . The method of claim 13 , wherein said sequencing comprises:

massively parallel sequencing-by-synthesis with reversible dye terminators;

sequencing-by-ligation; or

single molecule sequencing.

16 . The method of claim 13 , wherein said sequencing is performed on an amplified library preparation.

17 . The method of claim 13 , wherein said sequencing is next generation sequencing (NGS).

Assignments (2)

Continuity (8)

References Cited (400)